Literature DB >> 16533753

WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies.

Zheyu Li, Yoshihiro Oka, Akihiro Tsuboi, Tomoki Masuda, Naoko Tatsumi, Manabu Kawakami, Tatsuya Fujioka, Nao Sakaguchi, Hiroko Nakajima, Fumihiro Fujiki, Keiko Udaka, Yusuke Oji, Ichiro Kawase, Haruo Sugiyama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16533753     DOI： 10.1532/IJH97.05107

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  13 in total

1.  Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.

Authors:  Akihiro Tsuboi; Yoshihiro Oka; Keiko Udaka; Masaki Murakami; Tomoki Masuda; Akiko Nakano; Hiroko Nakajima; Masaki Yasukawa; Akio Hiraki; Yusuke Oji; Manabu Kawakami; Naoki Hosen; Tatsuya Fujioka; Fei Wu; Yuki Taniguchi; Sumiyuki Nishida; Momotaro Asada; Hiroyasu Ogawa; Ichiro Kawase; Haruo Sugiyama
Journal:  Cancer Immunol Immunother       Date:  2002-10-18       Impact factor: 6.968

2.  Cancer immunotherapy targeting Wilms' tumor gene WT1 product.

Authors:  Y Oka; K Udaka; A Tsuboi; O A Elisseeva; H Ogawa; K Aozasa; T Kishimoto; H Sugiyama
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

3.  Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity.

Authors:  V Mailänder; C Scheibenbogen; E Thiel; A Letsch; I W Blau; U Keilholz
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528

4.  Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL.

Authors:  Ilaria Bellantuono; Liquan Gao; Suzanne Parry; Steve Marley; Francesco Dazzi; Jane Apperley; John M Goldman; Hans J Stauss
Journal:  Blood       Date:  2002-11-15       Impact factor: 22.113

5.  Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.

Authors:  L Gao; I Bellantuono; A Elsässer; S B Marley; M Y Gordon; J M Goldman; H J Stauss
Journal:  Blood       Date:  2000-04-01       Impact factor: 22.113

6.  Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.

Authors:  Y Oka; O A Elisseeva; A Tsuboi; H Ogawa; H Tamaki; H Li; Y Oji; E H Kim; T Soma; M Asada; K Ueda; E Maruya; H Saji; T Kishimoto; K Udaka; H Sugiyama
Journal:  Immunogenetics       Date:  2000-02       Impact factor: 2.846

7.  Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF).

Authors:  A Tsuboi; Y Oka; H Ogawa; O A Elisseeva; H Tamaki; Y Oji; E H Kim; T Soma; T Tatekawa; M Kawakami; T Kishimoto; H Sugiyama
Journal:  Leuk Res       Date:  1999-05       Impact factor: 3.156

8.  Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Masaki Murakami; Manabu Hirai; Nobuhiko Tominaga; Hiroko Nakajima; Olga A Elisseeva; Tomoki Masuda; Akiko Nakano; Manabu Kawakami; Yusuke Oji; Kazuhiro Ikegame; Naoki Hosen; Keiko Udaka; Masaki Yasukawa; Hiroyasu Ogawa; Ichiro Kawase; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

9.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Tetsuya Taguchi; Tadashi Osaki; Taiichi Kyo; Hiroko Nakajima; Olga A Elisseeva; Yusuke Oji; Manabu Kawakami; Kazuhiro Ikegame; Naoki Hosen; Satoshi Yoshihara; Fei Wu; Fumihiro Fujiki; Masaki Murakami; Tomoki Masuda; Sumiyuki Nishida; Toshiaki Shirakata; Shin-Ichi Nakatsuka; Ayako Sasaki; Keiko Udaka; Hiroo Dohy; Katsuyuki Aozasa; Shinzaburo Noguchi; Ichiro Kawase; Haruo Sugiyama
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-13       Impact factor: 11.205

10.  Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis.

Authors:  T Yamagami; H Sugiyama; K Inoue; H Ogawa; T Tatekawa; M Hirata; T Kudoh; T Akiyama; A Murakami; T Maekawa
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113
View more
  1 in total

1.  Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA.

Authors:  Miwako Narita; Nozomi Tochiki; Anri Saitoh; Norihiro Watanabe; Masami Kaji; Noriyuki Satoh; Akie Yamahira; Takeshi Nakamura; Masayoshi Masuko; Tatsuo Furukawa; Ken Toba; Ichiro Fuse; Yoshifusa Aizawa; Masuhiro Takahashi
Journal:  Med Oncol       Date:  2008-12-05       Impact factor: 3.064
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.